CTSS and osteoporosis: While inhibitors of cathepsin B and S are currently being evaluated in clinical trials, recent failure of Odanacatib, a cathepsin K inhibitor for osteoporosis, in late stage clinical trial has made pharmaceutical industries wary of targeting cathepsins.